title: The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective.
abstract: Glaucoma is a condition affecting one or both eyes with raised intraocular pressure (IOP). IOP should be reduced to prevent progression of visual field loss. This study investigates the cost-effectiveness of bimatoprost compared with latanoprost as first-line monotherapies in the treatment of glaucoma in Austria, Finland and France. On the basis of a single multicentre, randomised, investigator-masked controlled trial, a 6- and 12-month cost-effectiveness model was designed following the treatment recommendations from the European Glaucoma Society. Treatment changes due to insufficient IOP reduction and adverse events were included. The cost-effectiveness analysis showed that the need for adjunctive therapy was the major cost driver. On the basis of evidence from the randomised, investigator-masked clinical trial (RCT), the cost-effectiveness analysis found that bimatoprost was a cheaper and a more effective treatment strategy compared with latanoprost. This was true for all three countries and all IOP targets between 13 and 20 mmHg. The cost-effectiveness result may be generalised to a European setting and perspective.
authors.affiliation: CHNO des Quinze Vingts, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Tuil
authors.forename: A B
authors.initials: AB
authors.lastname: Hommer
authors.forename: P B
authors.initials: PB
authors.lastname: Poulsen
authors.forename: T L
authors.initials: TL
authors.lastname: Christensen
authors.forename: P
authors.initials: P
authors.lastname: Buchholz
authors.forename: J
authors.initials: J
authors.lastname: Walt
authors.forename: S
authors.initials: S
authors.lastname: Holmstrom
mesh_terms: D000577:Amides; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D001317:Austria; D000069580:Bimatoprost; D017024:Chemotherapy, Adjuvant / Q000191:economics; D003008:Cloprostenol / Q000031:analogs & derivatives; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005387:Finland; D005602:France; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D000077338:Latanoprost; D008055:Lipids / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D018803:Models, Economic; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost